KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Inventory (2016 - 2025)

Historic Inventory for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $28.6 million.

  • Neogenomics' Inventory rose 679.68% to $28.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $28.6 million, marking a year-over-year increase of 679.68%. This contributed to the annual value of $28.6 million for FY2025, which is 679.68% up from last year.
  • As of Q4 2025, Neogenomics' Inventory stood at $28.6 million, which was up 679.68% from $28.5 million recorded in Q3 2025.
  • Neogenomics' Inventory's 5-year high stood at $34.2 million during Q2 2025, with a 5-year trough of $20.3 million in Q1 2024.
  • Moreover, its 5-year median value for Inventory was $24.1 million (2023), whereas its average is $24.8 million.
  • Per our database at Business Quant, Neogenomics' Inventory crashed by 2076.47% in 2021 and then surged by 4720.0% in 2025.
  • Neogenomics' Inventory (Quarter) stood at $23.4 million in 2021, then increased by 3.77% to $24.3 million in 2022, then decreased by 0.5% to $24.2 million in 2023, then grew by 10.73% to $26.7 million in 2024, then increased by 6.8% to $28.6 million in 2025.
  • Its Inventory was $28.6 million in Q4 2025, compared to $28.5 million in Q3 2025 and $34.2 million in Q2 2025.